tipifarnib has been researched along with azomycin in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (azomycin) | Trials (azomycin) | Recent Studies (post-2010) (azomycin) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 4,790 | 418 | 1,580 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL | 1 |
1 other study(ies) available for tipifarnib and azomycin
| Article | Year |
|---|---|
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Alkyl and Aryl Transferases; Animals; Chagas Disease; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Humans; Mice; Models, Molecular; Nitroimidazoles; Quinolones; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2012 |